tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Andreas Argyrides, 123 are a BUY (84.83%), 20 are a HOLD (13.79%), 2 are a SELL (1.38%).
Analyst Andreas Argyrides, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 38.48% that have a potential upside of 46.69% achieved within 153 days. Previously, Andreas Argyrides worked at OPPENHEIMER.
Andreas Argyrides’s has documented 289 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MNKD, MannKind Corp.
Analyst best performing recommendations are on MNPR (MONOPAR THERAPEUTICS).
The best stock recommendation documented was for MNPR (MONOPAR THERAPEUTICS) at 9/3/2025. The price target of $77 was fulfilled within 22 days with a profit of $40.79 (112.65%) receiving and performance score of 51.2.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 11-Mar-2024
$21
$14.07 (203.03%)
$23
1 months 27 days ago
(25-Aug-2026)
0/20 (0%)
$12.09 (135.69%)
Buy Since 02-Jun-2023
$29
$22.07 (318.47%)
$32
1 months 27 days ago
(25-Aug-2026)
0/9 (0%)
$20.09 (225.48%)
Buy Since 07-Aug-2026
$12
$5.07 (73.16%)
$47
2 months 15 days ago
(07-Aug-2026)
1/2 (50%)
$1.28 (11.94%)
12
Buy Since 15-Dec-2025
$18
$7.52 (71.76%)
$20
4 months ago
(22-Jun-2026)
15/18 (83.33%)
$8.93 (98.46%)
117
Buy Since 31-Oct-2023
$42
$35.07 (506.06%)
$42
4 months 25 days ago
(27-May-2026)
0/12 (0%)
$35.31 (527.80%)
Which stock is Andreas Argyrides most bullish on?
Which stock is Andreas Argyrides most reserved on?
What Year was the first public recommendation made by Andreas Argyrides?
